Sun Pharmaceutical Industries Limited announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection in India for chronic weight management in adults.

Semaglutide, a GLP-1 receptor agonist, is indicated as an adjunct to a reduced-calorie diet and increased physical activity. Sun Pharma will launch the product under the brand name Noveltreat after the expiry of the semaglutide patent in India.

The approval follows a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths—0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL—with a recommended maintenance dose of 2.4 mg once weekly. The drug will be administered through a prefilled pen designed for convenient and accurate dosing.

Commenting on the development, Kirti Ganorkar, Managing Director, Sun Pharma, said that obesity and diabetes are emerging as major public health challenges in India, and GLP-1–based therapies can play a meaningful role in addressing this burden. He added that Sun Pharma is committed to improving access to high-quality generic semaglutide following patent expiry.

Dr. Unnikrishnan A G, Chief Endocrinologist and CEO of Chellaram Diabetes Institute, noted that GLP-1 receptor agonists represent a significant advancement in metabolic health but should be used alongside lifestyle modifications and under medical supervision.

In December 2025, Sun Pharma had also received DCGI approval to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes mellitus, to be launched under the brand name Sematrinity after patent expiry in India.